Uses of Ausulvas

1 Ausulvas tablet contains 10mg Rosuvastatin (as Rosuvastatin Calci). Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, an enzyme that catalyzes the conversion of 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate (a cholesterol precursor).
The major site of action of Rosuvastatin is the liver - the target organ for cholesterol lowering. Rosuvastatin increases the number of LDL receptors on the surface of hepatocytes, increases the absorption and catabolism of LDL, inhibits the synthesis of VLDL in the liver, reduces the components of LDL and VLDL.
In addition, Rosuvastatin also has many other uses:
Anti-atherosclerotic, slow the progression or regress of coronary and carotid atherosclerosis; Reducing blood pressure in patients with hypertension and primary hypercholesterolemia; In patients with hypercholesterolemia, Rosuvastatin has anti-inflammatory activity; Increases bone density. Indications for use of Ausulvas
Treatment of hypercholesterolemia: An adjunct to dietary therapy to reduce total and LDL cholesterol levels in patients with primary hypercholesterolemia with little reduction in triglycerides; Primary prevention of coronary events: In patients with hypercholesterolemia without clinically evident coronary artery disease, the drug is used to reduce the risk of myocardial infarction, reduce the risk of reconstructive procedures. coronary heart disease and reduce the risk of death from cardiovascular disease; Treatment of Atherosclerosis: In hypercholesterolemic patients with clinical manifestations of coronary artery disease (including previous myocardial infarction), the drug is used to slow the progression of coronary atherosclerosis and reduce the risk of coronary artery disease. risk of acute coronary events. Contraindications to the use of Ausulvas
Patients with hypersensitivity to Rosuvastatin or other components of the drug; Patients with active liver disease or unexplained persistent elevations in serum transaminases; Pregnant women (or suspected of being pregnant), mothers who are breastfeeding; People taking drugs: Gemfibrozil, fibrate-lowering blood cholesterol, high-dose Niacin (over 1g/day), Colchicin, drugs for HIV and hepatitis C (such as atazanavir, lopinavir + ritonavir, atazanavir + ritonavir).

Usage: Orally. Because cholesterol synthesis in the liver mainly occurs at night, taking Ausulvas in the evening will increase the effectiveness of the drug.
Dosage:
Dosage of Ausulvas drug follow the doctor's instructions. Patients should follow a low cholesterol diet before taking Ausulvas and should continue to maintain this diet for the duration of the drug. Treatment with Ausulvas should be started with the lowest effective dose. After that, if necessary, the dose can be adjusted according to the needs and response of each patient by increasing the dose at intervals of not less than 4 weeks, while monitoring for adverse drug reactions (especially for the musculoskeletal system). Refer to the following dosage:
Starting dose: 5mg; Maximum maintenance dose: 40mg; Patients with renal impairment: The dose of Ausulvas should be reduced as prescribed by the doctor. Note: All patients started at 10mg once daily, only increased to 20mg if needed after 4 weeks. Close monitoring is recommended for patients receiving doses up to 40 mg.
Overdose: When using Ausulvas drug overdose, there is no specific treatment. The treatment of choice for overdose is mainly symptomatic and supportive measures necessary.

When using Ausulvas, patients may experience some side effects such as:
Digestion: Constipation, diarrhea, abdominal pain, flatulence, nausea; Central nervous system: Dizziness, headache, weakness, blurred vision, insomnia; Neuromuscular and skeletal: Arthralgia, myalgia; Liver: Changes in liver function tests. When experiencing unwanted side effects due to the use of Ausulvas, patients should immediately notify their doctor to receive appropriate advice.

Some notes for patients to keep in mind before and while taking Ausulvas:
Before starting treatment with Rosuvastatin, the causes of hypercholesterolemia should be excluded such as hypothyroidism, poorly controlled diabetes, disorders. blood protein, nephrotic syndrome, alcoholism, obstructive liver disease, due to the use of some drugs,... At the same time, it is necessary to measure total cholesterol, HDL, LDL and triglycerides; Lipid measurements should be performed at regular intervals (at intervals of not less than 4 weeks) for patients receiving Ausulvas and the dose should be adjusted according to the patient's response. The goal of treatment is to reduce LDL, so it is necessary to base on LDL levels to initiate treatment and assess treatment response. Only when LDL testing is not available should total cholesterol therapy be used; In clinical trials, a small number of patients taking statins experienced marked increases in serum transaminases. When drug is discontinued in patients, transaminase levels usually fall slowly to pre-dosing levels. Some patients before taking the drug had abnormal liver function test results or drank a lot of alcohol. Therefore, liver enzyme testing should be performed prior to initiating statin therapy and, in cases where clinical indications require it, to be performed thereafter. The drug should be used with caution in patients who drink heavily, have a history of liver disease; If serum transaminase levels AST or ALT persist to more than 3 times the upper limit of normal, statin therapy should be discontinued; Patients taking statins should immediately report any symptoms such as unexplained muscle pain, tenderness, and weakness, especially if accompanied by malaise or fever. Statin therapy should be discontinued if CPK levels are markedly elevated (more than 10 times the upper limit of normal) and if myopathy is diagnosed or suspected; Because Ausulvas can cause dizziness as a side effect, drivers and machine operators should pay attention to this symptom in order to use the drug appropriately; Rosuvastatin can harm an unborn baby if used by a pregnant woman. Therefore, the use of Ausulvas is contraindicated in pregnant women; Due to the possible risk of adverse effects in nursing infants, the use of Ausulvas is contraindicated in nursing mothers.

Some drug interactions of Ausulvas include:
The risk of myositis and rhabdomyolysis is increased in patients receiving combination therapy with Rosuvastatin with erythromycin, itraconazole, cyclosporin, ketoconazole due to inhibition of cytochrome CYP3A4; Increased risk of muscle damage when Rosuvastatin is used concurrently with gemfibrozil, high dose Niacin (over 1g/day), colchicine, other fibrate-lowering cholesterol drugs; Concomitant use of Rosuvastatin with HIV and hepatitis C drugs such as atazanavir, atazanavir + ritonavir, lopinavir + ritonavir may increase the risk of muscle damage, most seriously rhabdomyolysis, kidney failure leading to failure kidneys, which can be fatal; Rosuvastatin may increase the effect of the anticoagulant Warfarin. Therefore, prothrombin time should be determined before initiating statin use and should be regularly monitored during the initial phase of treatment to ensure that there is no significant change in prothrombin time; When Rosuvastatin is co-administered with bile acid-binding resins, the bioavailability of Rosuvastatin is markedly reduced. Therefore, it is advisable to ensure that the two drugs are taken at a distance from each other. When prescribed by a doctor to use Ausulvas, the patient should strictly follow the detailed instructions, should not arbitrarily change the dose, use, and duration of the drug. As a result, patients will ensure effective treatment and significantly reduce the risk of dangerous events.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.